FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559547810> ?p ?o ?g. }

• W2559547810 abstract "Abstract Autologous stem cell transplantation (ASCT) is widely used in young/adult patients with acute myeloid leukemia (AML). However, ASCT is also feasible in elderly AML patients with encouraging results in terms of relapse rate reduction. The combination of fludarabine (F) with cytarabine (ARA-C) is effective in poor risk AML and advanced myelodysplastic syndromes (MDS); however, the administration of F can result in insufficient collection of CD34+ cells. We investigated the mobilization capacity from 28 untreated non M3 elderly AML patients who achieved complete remission (CR) after F plus ARA-C given as continuous sequential infusion (CI-FLA). F was administered at a loading dose of 10 mg/sqm over 15 min at day 0 followed by a continuous infusion (CI) of 20 mg/sqm/24h for 72 hours. ARA-C was given at a loading dose of 390 mg/sqm over 15 min three hours and half after F and then as CI over 96 hours at 1440 mg/sqm/24h. G-CSF was added at day +15 at 5 microg/kg. Patients in CR were programmed to receive an identical course. However, after the first 20 patients, consolidation was reduced by one day because of excessive toxicity. G-CSF at 10 microg/kg was added at day +15 with the aim of shortening neutropenia and mobilizing CD34+ cells. Between December 2001 and April 2004, 62 patients with a median age of 69 years (61–81) received the therapeutic program. In 24 cases (39%) a previously diagnosed MDS preceded the onset of AML. According to MRC criteria, 29 patients (47%) had intermediate karyotype, 23 (37%) adverse karyotype, 1 (2%) favorable karyotype and 9 (14%) no evaluable metaphases. Overall, 41 patients (66%) achieved CR, all following one course of CI-FLA. Among these, 34 (83%) received the programmed consolidation, while in 7 cases therapy was discontinued due to toxicity (n=5), death from cerebral hemorrage (n=1), loss to follow-up (n=1). There were 6 deaths after consolidation (4 from infections and 2 from miocardial infarction apparently unrelated to chemotherapy). Finally, 28 patients were monitorized for the mobilization which was successful in 22/28 patients (78%), with a median collection of 7.5x10E6 CD34+ cells (2,1–60,3). The median number of apheresis was 2 (1–3). The median age of mobilizers was 68 years (61–77); of note, 12/28 of them (43%) had secondary AML and 9 (41%) were aged over 70 years. There was no difference in CD34+ mobilization between patients consolidated with three or four days of therapy (p=0.78). Median time from the beginning of consolidation to first collection was 19 days (17–29). Overall, 17 patients (27% of the whole population, 41% of remitters and 77% of mobilizers) received ASCT, in absence of transplant related death. The median age of autografted patients was 66 years (61–77). Reasons for not autografting included early relapse (n=1), refusal (n=1), infection (n=2), severe uncontrolled diabetes resulting in left foot gangrene (n=1). In conclusion, this study demonstrates that continuous sequential infusion of F + ARA-C is effective in elderly AML patients with acceptable toxicity and high rate of CD34+ cell mobilization. In particular, our results compare favorably with classical combination of anthracyclines plus ARA-C or conventional F+ARA-C in terms of mobilization. We suggest that F, when given as continuous infusion, results in negligible stem cell damage and therefore in less impairment of mobilization capacity." @default.
• W2559547810 created "2016-12-08" @default.
• W2559547810 creator A5042609656 @default.
• W2559547810 creator A5060752899 @default.
• W2559547810 creator A5072941996 @default.
• W2559547810 creator A5076571467 @default.
• W2559547810 creator A5085216234 @default.
• W2559547810 date "2004-11-16" @default.
• W2559547810 modified "2023-10-16" @default.
• W2559547810 title "The Combination of Fludarabine + ARA-C Given as Continuous Sequential Infusion Does Not Hamper Mobilization of Stem Cells in Elderly Patients with Acute Myeloid Leukemia." @default.
• W2559547810 doi "https://doi.org/10.1182/blood.v104.11.5208.5208" @default.
• W2559547810 hasPublicationYear "2004" @default.
• W2559547810 type Work @default.
• W2559547810 sameAs 2559547810 @default.
• W2559547810 citedByCount "0" @default.
• W2559547810 crossrefType "journal-article" @default.
• W2559547810 hasAuthorship W2559547810A5042609656 @default.
• W2559547810 hasAuthorship W2559547810A5060752899 @default.
• W2559547810 hasAuthorship W2559547810A5072941996 @default.
• W2559547810 hasAuthorship W2559547810A5076571467 @default.
• W2559547810 hasAuthorship W2559547810A5085216234 @default.
• W2559547810 hasConcept C126322002 @default.
• W2559547810 hasConcept C141071460 @default.
• W2559547810 hasConcept C2776694085 @default.
• W2559547810 hasConcept C2776755627 @default.
• W2559547810 hasConcept C2777063308 @default.
• W2559547810 hasConcept C2777767877 @default.
• W2559547810 hasConcept C2778041864 @default.
• W2559547810 hasConcept C2778461978 @default.
• W2559547810 hasConcept C2778729363 @default.
• W2559547810 hasConcept C2778850193 @default.
• W2559547810 hasConcept C2779050716 @default.
• W2559547810 hasConcept C2779263901 @default.
• W2559547810 hasConcept C2911091166 @default.
• W2559547810 hasConcept C29730261 @default.
• W2559547810 hasConcept C71924100 @default.
• W2559547810 hasConcept C90924648 @default.
• W2559547810 hasConceptScore W2559547810C126322002 @default.
• W2559547810 hasConceptScore W2559547810C141071460 @default.
• W2559547810 hasConceptScore W2559547810C2776694085 @default.
• W2559547810 hasConceptScore W2559547810C2776755627 @default.
• W2559547810 hasConceptScore W2559547810C2777063308 @default.
• W2559547810 hasConceptScore W2559547810C2777767877 @default.
• W2559547810 hasConceptScore W2559547810C2778041864 @default.
• W2559547810 hasConceptScore W2559547810C2778461978 @default.
• W2559547810 hasConceptScore W2559547810C2778729363 @default.
• W2559547810 hasConceptScore W2559547810C2778850193 @default.
• W2559547810 hasConceptScore W2559547810C2779050716 @default.
• W2559547810 hasConceptScore W2559547810C2779263901 @default.
• W2559547810 hasConceptScore W2559547810C2911091166 @default.
• W2559547810 hasConceptScore W2559547810C29730261 @default.
• W2559547810 hasConceptScore W2559547810C71924100 @default.
• W2559547810 hasConceptScore W2559547810C90924648 @default.
• W2559547810 hasLocation W25595478101 @default.
• W2559547810 hasOpenAccess W2559547810 @default.
• W2559547810 hasPrimaryLocation W25595478101 @default.
• W2559547810 hasRelatedWork W1976678201 @default.
• W2559547810 hasRelatedWork W2070044750 @default.
• W2559547810 hasRelatedWork W2373000763 @default.
• W2559547810 hasRelatedWork W2461234028 @default.
• W2559547810 hasRelatedWork W2472873444 @default.
• W2559547810 hasRelatedWork W2534388651 @default.
• W2559547810 hasRelatedWork W2559547810 @default.
• W2559547810 hasRelatedWork W2734477894 @default.
• W2559547810 hasRelatedWork W2963069925 @default.
• W2559547810 hasRelatedWork W3025300208 @default.
• W2559547810 isParatext "false" @default.
• W2559547810 isRetracted "false" @default.
• W2559547810 magId "2559547810" @default.
• W2559547810 workType "article" @default.